

Paracetamol - flu - India (Repurposing Scan)

Report ID: REP-20251217-eafdf8

Generated At: 2025-12-17T11:19:36.185794

Format: pdf

Executive Summary

- Current clinical publications on paracetamol for flu specifically in humans in the recent years within India are sparse. Existing studies found mainly on pharmacokinetics in non-human models or in vitro experimental approaches. Authoritative flu-specific guidelines from WHO and NICE do not specifically elaborate paracetamol use but provide general management approaches. Recent Indian news highlights flu surges with symptomatic management challenges; warnings are issued regarding safe paracetamol dosing amid the flu season, and reports suggest that paracetamol may not fully ease flu-related fever for many. Overall, while paracetamol is commonly used symptomatically in flu, strong contemporary evidence for efficacy or new repurposing insights specifically in the flu indication is lacking. Safety considerations remain important in the context of prevalent use in India.

Clinical Trials

Summary

- Active trials: 1
- Completed trials: 4
- Phase distribution: Phase Observational (0) Phase Phase 1 (1) Phase Phase 2 (0) Phase Phase 3 (3) Phase Phase 4 (0)

Highlights

- No Phase III trials identified in India

Top Trials

Trial ID	Title	Phase	Status	Locations	Start Date
NCT01389518	Evaluation of the Efficacy and Safety of Fixed Combination of Paracetamol, Chlorpheniramine and	Phase 3	Completed	Not available	2009-05

Trial ID	Title	Phase	Status	Locations	Start Date
	Phenylephrine in the Treatment of Symptomatic Common Cold and Flu Syndrome in Adults				
NCT05901636	A Randomized, Double-blind, Placebo-controlled, First-in-human Phase 1/2a Study to Evaluate Safety, Reactogenicity and Immunogenicity of a Universal Influenza (Uniflu) Vaccine With INFLUENZA G1 mHA in Healthy Adults	Phase 1	Completed	United States	2023-05-17
NCT05474755	A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Acute Uncomplicated Influenza	Phase 3	Completed	China	2022-07-28
NCT05375864	Prognostic Impact of Early Oseltamivir Carboxylate Low Plasma Concentration in Critically Ill Patients With Severe Influenza: a Prospective Cohort Study	NA	Active	France	2022-12-01
NCT01158326	Evaluation of Efficacy and Safety of Oral Solution Paracetamol, Maleate Chlorpheniramine and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu: a Double-blind	Phase 3	Completed	Brazil	2010-08

Guidelines and Literature

Guidelines

- **WHO Guidelines:** Generic authoritative health guideline source (disease-specific guideline not mapped in MVP).

- **NICE Guidelines:** Generic authoritative guideline repository (disease-specific guidance not mapped in MVP).

Publications

- **PMID 36840424 (2023):**
- **PMID 36264934 (2022):**

Repurposing Options

• Targeted subgroup usage

Rationale: Current clinical publications on paracetamol for flu specifically in humans in the recent years within India are sparse. Existing studies found mainly on pharmacokinetics in non-human models or in vitro experimental approaches. Authoritative flu-specific guidelines from WHO and NICE do not specifically elaborate paracetamol use but provide general management approaches. Recent Indian news highlights flu surges with symptomatic management challenges; warnings are issued regarding safe paracetamol dosing amid the flu season, and reports suggest that paracetamol may not fully ease flu-related fever for many. Overall, while paracetamol is commonly used symptomatically in flu, strong contemporary evidence for efficacy or new repurposing insights specifically in the flu indication is lacking. Safety considerations remain important in the context of prevalent use in India.

Evidence: WHO Guidelines, NICE Guidelines

Risks and Gaps

- Limited late-stage clinical evidence
- Geography-specific data gaps for India

References

- **Guideline:** WHO Guidelines — <https://www.who.int/publications/guidelines>
- **Guideline:** NICE Guidelines — <https://www.nice.org.uk/guidance>
- **Publication:** PMID:36840424 — <https://pubmed.ncbi.nlm.nih.gov/36840424/>
- **Publication:** PMID:36264934 — <https://pubmed.ncbi.nlm.nih.gov/36264934/>
- **Trial:** NCT01389518 — <https://clinicaltrials.gov/study/NCT01389518>
- **Trial:** NCT05901636 — <https://clinicaltrials.gov/study/NCT05901636>
- **Trial:** NCT05474755 — <https://clinicaltrials.gov/study/NCT05474755>
- **Trial:** NCT05375864 — <https://clinicaltrials.gov/study/NCT05375864>
- **Trial:** NCT01158326 — <https://clinicaltrials.gov/study/NCT01158326>

Warnings

- **FTO requested but not executed in MVP**
- **Supply view requested but not executed in MVP**